References
- Swerdlow SH, Webber SA, Chadburn A, . Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 343–349.
- Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4: 222–230.
- Parker A, Bowles K, Bradley JA, . Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149:693–705.
- Kaito K, Kobayashi M, Katayama T, . Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997;59:247–253.
- Henter JI, Samuelsson-Horne A, Arico M, . Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002;100: 2367–2373.
- Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2005:82–88.
- Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009: 127–131.
- Ponticelli C, Alberighi OD. Haemophagocytic syndrome--a life-threatening complication of renal transplantation. Nephrol Dial Transplant 2009;24:2623–2627.
- Lehmkuhl H, Ross H, Eisen H, . Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005;37: 4145–4149.
- Pascual J. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007;22(Suppl. 1):i27–i35.
- Quinlan SC, Pfeiffer RM, Morton LM, . Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011;86:206–209.
- Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, . Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95: 1342–1349.
- Hsi ED, Lorsbach RB, Fend F, . Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011;136:183–194.
- Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology 2007;51:774–777.
- Apichai S, Rogalska A, Tzvetanov I, . Multifocal cutaneous and systemic plasmablastic lymphoma in an infant with combined living donor small bowel and liver transplant. Pediatr Transplant 2009;13:628–631.
- Beltran B, Castillo J, Salas R, . ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009;2:11.
- Bose P, Thompson C, Gandhi D, . AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 2009;82:490–492.
- Montes-Moreno S, Montalban C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma 2012;53:185–194.
- Tierney LM Jr, Thabet A, Nishino H. Case records of the Massachusetts General Hospital. Case 10 - 2011. A woman with fever, confusion, liver failure, anemia, and thrombocytopenia. N Engl J Med 2011;364:1259–1270.
- Imashuku S, Kuriyama K, Teramura T, . Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19: 2665–2673.